NIKA PHARMACEUTICALS, INC (NIKA) Form 10-Q — Aug 10, 2026
Nika Pharmaceuticals filed its 10-Q for the quarter ended June 30, 2026 reporting zero revenue and a net loss of $19,694, versus an $18,381 loss in the year-ago quarter. The company states that its $9,037,063 accumulated deficit and lack of income to date raise substantial doubt about its ability to continue as a going concern. The balance sheet shows just $2,932 in cash against $340,624 due to related parties, producing a stockholders' deficit of $330,682. Operations are funded entirely by non-interest-bearing, due-on-demand loans from CEO Dimitar Slavchev Savov and affiliated Bulgarian entities.
Key figures
- Eps
- 0
- Revenue
- 0
- Total Assets
- 9942
- Cash Position
- 2932
- Shares Outstanding
- 1051689224
- Accumulated Deficit
- 9037063
- Due To Related Parties
- 340624
- Related Party Loans Six Months
- 22000
- Weighted Average Shares Basic And Diluted
- 1051689224
- Q1 2026 Prepaid Amortization Timing Correction
- 7820
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.